諾華製藥
Open
Market Cap
High
Low
Close
Volume
P/E Ratio
Div/Yield
About 諾華製藥
Novartis AG 在全球範圍內研究、開發、製造和銷售保健產品。該公司通過兩個部門運營，即 Innovative Medicines 和 Sandoz。創新藥物部門為患者和醫療保健提供者提供處方藥。它還提供眼科、神經科學、免疫學、肝病學、皮膚病學、呼吸、心血管、腎臟和代謝醫學產品。 Sandoz——開發、製造和銷售成品劑型藥物；向第三方提供小分子藥物的活性成分和成品劑型；零售仿製藥和抗感染藥。它還提供以抗生素為主的藥物活性成分和中間體；蛋白質或其他基於生物技術的產品，包括生物仿製藥；和生物技術製造服務。 Novartis AG 與 Alnylam Pharmaceuticals 簽訂了開發、製造和商業化 inclisiran 的許可和合作協議；以及與 Kura Oncology, Inc. 的臨床合作，以評估 Tipifarnib 和 Alpelisib 聯合治療頭頸部鱗狀細胞癌患者的療效。公司成立於1996年，總部位於瑞士巴塞爾。
如何購買 諾華製藥 (NVS)
登入
1分鐘開戶
僅需1分鐘即可完成帳戶申請和驗證。整個過程完全自助，支援 RockFlow App 和網頁端操作。
充值資金
帳戶驗證完成後，您可以使用首選的支付方式向帳戶充值。
購買 NVS
透過 RockFlow App 或網頁端搜尋 NVS，輸入您想要投資的金額，然後點擊確認即可完成交易。
© Rockalpha Limited. All Rights Reserved.
Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider. Rockalpha Limited is not licensed by a New Zealand regulator to provide the client money or property services, and Rockalpha Limited’s registration on the New Zealand register of financial service providers or membership of the Insurance & Financial Services Ombudsman Scheme does not mean that Rockalpha Limited is subject to active regulation or oversight by a New Zealand regulator.Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider.